Last reviewed · How we verify

Continuation of oral anticoagulants

St. Antonius Hospital · FDA-approved active Small molecule

Continuation of oral anticoagulants is a Anticoagulant Small molecule drug developed by St. Antonius Hospital. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis.

Oral anticoagulants prevent blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.

Oral anticoagulants prevent blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis.

At a glance

Generic nameContinuation of oral anticoagulants
SponsorSt. Antonius Hospital
Drug classAnticoagulant
TargetCoagulation cascade factors (Factor II, VII, IX, X, or direct Factor Xa/IIa inhibition depending on specific agent)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Oral anticoagulants work through two main classes: vitamin K antagonists (e.g., warfarin) that inhibit factors II, VII, IX, and X, and direct oral anticoagulants (DOACs) that directly inhibit factor Xa or thrombin (factor IIa). Both mechanisms reduce the ability of blood to clot, thereby preventing pathological thrombus formation in conditions prone to thromboembolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Continuation of oral anticoagulants

What is Continuation of oral anticoagulants?

Continuation of oral anticoagulants is a Anticoagulant drug developed by St. Antonius Hospital, indicated for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis.

How does Continuation of oral anticoagulants work?

Oral anticoagulants prevent blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.

What is Continuation of oral anticoagulants used for?

Continuation of oral anticoagulants is indicated for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis, Post-surgical thromboprophylaxis.

Who makes Continuation of oral anticoagulants?

Continuation of oral anticoagulants is developed and marketed by St. Antonius Hospital (see full St. Antonius Hospital pipeline at /company/st-antonius-hospital).

What drug class is Continuation of oral anticoagulants in?

Continuation of oral anticoagulants belongs to the Anticoagulant class. See all Anticoagulant drugs at /class/anticoagulant.

What development phase is Continuation of oral anticoagulants in?

Continuation of oral anticoagulants is FDA-approved (marketed).

What are the side effects of Continuation of oral anticoagulants?

Common side effects of Continuation of oral anticoagulants include Bleeding (major and minor), Gastrointestinal bleeding, Intracranial hemorrhage, Dyspepsia.

What does Continuation of oral anticoagulants target?

Continuation of oral anticoagulants targets Coagulation cascade factors (Factor II, VII, IX, X, or direct Factor Xa/IIa inhibition depending on specific agent) and is a Anticoagulant.

Related